RxDoctor Payments Data

Jason Konner, MD

Internal Medicine · New York, NYNPI 1710958509

Payments from drug & device makers

$186,782in general payments, 2019–2025

Across 44 payments — averaging $4245.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$114K
  • Immunogen, Inc.$39K
  • AstraZeneca$25K
  • AbbVie$4K
  • Clovis Oncology, Inc.$2K
  • Merck$2K
  • plus $45 from 1 others

What the payments were for

  • Consulting fees$18,91391%
  • Travel & lodging$1,4717%
  • Food & beverage$2871%
  • Education$450%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.2$114,376
Immunogen, Inc.14$38,731
AstraZeneca15$24,862
AbbVie9$4,128
Clovis Oncology, Inc.1$2,400
Merck1$2,240
Daiichi Sankyo Inc.2$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,782 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$123,388
Medicare patients
217
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate26$574,835
LynparzaOlaparib15$202,461
XareltoRivaroxaban17$18,843
Prednisolone Acetate21$1,343
Dexamethasone76$1,031
Ondansetron Hcl60$928
Lorazepam65$722
Oxycodone Hcl30$506
Letrozole22$457
Gabapentin35$337
Potassium Chloride19$244
Montelukast Sodium40$222
Pantoprazole Sodium33$198
Prednisone27$146
Citalopram HbrCitalopram Hydrobromide14$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$24,862$202,46115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →